IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IRADIMED CORPORATION on December 17, 2015, with the report date reflecting the earliest event of December 17, 2015. The filing details the entry into a material definitive agreement regarding a public secondary offering of common stock by a selling stockholder.
Key Financial Metrics and Transaction Details
- Transaction Type: Public secondary offering (shares sold by a stockholder, not the company).
- Shares Offered: 1,043,479 shares of common stock.
- Offering Price: $24.25 per share.
- Overallotment Option: Underwriter granted a 30-day option to purchase up to 156,521 additional shares.
- Net Proceeds: Approximately $27,936,000 expected to be received by the Selling Stockholder (Roger Susi, as trustee of the Roger E. Susi Revocable Trust) after underwriting discounts and expenses, assuming full exercise of the overallotment option.
- Company Proceeds: The filing does not indicate that the Company receives proceeds from this secondary offering.
- Financial Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures for the Company.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with Roth Capital Partners, LLC. Key terms include:
- Lock-Up Agreements: Directors and executive officers agreed to a 60-day lock-up period. The Selling Stockholder agreed to a 90-day lock-up period.
- Closing Date: Expected on or about December 23, 2015.
- Registration: The offering was made pursuant to an effective Form S-3 registration statement declared effective on December 7, 2015.
Outlook, Risks, and Management Commentary
The filing does not contain management commentary on business outlook, risks, or contingencies beyond the standard representations and warranties in the Underwriting Agreement. The transaction is subject to customary closing conditions. The Company issued press releases on December 18, 2015, regarding pricing terms and on December 23, 2015, announcing the closing of the transaction.
Investor Verification Checklist
- Verify the final closing date and whether the overallotment option was exercised.
- Confirm the exact net proceeds received by the Selling Stockholder versus the estimated $27.9 million.
- Review the Company's subsequent filings (e.g., 10-Q or 10-K) for any impact on share count and dilution, noting that the Company did not receive capital from this transaction.
- Check for any changes in the Selling Stockholder's ownership percentage post-offering.